Introduction
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a curative treatment for patients with myelodysplastic syndrome (MDS). [1] [2] [3] [4] While there is little chance of curing MDS by conventional measures, the timing and method of allo-SCT must still be refined, since allo-SCT is associated with a considerable transplant-related mortality. Recently, Cutler et al showed using a decision analysis that delayed BMT just before leukemic transformation is associated with maximal life-expectancy for patients with low-and intermediate-1-risk MDS grouped by the International Prognostic Scoring System (IPSS), 5 while immediate transplantation for intermediate-2-and high-risk disease is associated with maximal life-expectancy. 6 However, it is controversial whether remission induction chemotherapy should be performed before allo-SCT for MDS. 7 We retrospectively analyzed the outcome of 283 Japanese adult patients who received allo-SCT from an HLA-identical sibling donor and were registered with the Japan Society for Hematopoietic Cell Transplantation (JSHCT). The primary object of this study was to evaluate the impact of chemotherapy before allo-SCT on the outcome of allo-SCT.
Patients and methods

Patients
A total of 439 patients who underwent allo-SCT from an HLAidentical sibling donor for the first time between 1991 and 2001 for refractory anemia (RA), RA with ringed sideroblasts (RARS), RA with excess blasts (RAEB), RAEB in transformation (RAEB-t), chronic myelomonocytic leukemia (CMML), or transformation to acute myeloid leukemia (leukemic transformation (LT) were reported to the JSHCT. The diagnosis and classification of MDS was performed using the French-American-British (FAB) criteria. 8 Those younger than 16 years (n ¼ 8), those with a previous history of SCT (n ¼ 1), those who received a graft from a syngeneic donor (n ¼ 9), those who received a nonmyeloablative or reduced-intensity regimen (n ¼ 25), and those for whom we lacked information regarding the history of chemotherapy before transplantation (n ¼ 113) were excluded. Finally, 283 patients were analyzed. This study was approved by the Committee for Nationwide Survey Data Management of JSHCT. The blast cell count before allo-SCT was not included in the data set.
Cytogenetic evaluation
Cytogenetic data were available in 232 patients (82%). Patients were grouped according to the karyotype classification in IPSS. 5 Briefly, those who had a normal, del (5q), del (20q) or -Y karyotype, those who had complex abnormalities or chromosome 7 anomalies, and those who had other abnormalities were categorized into good, poor, and intermediate groups, respectively. In all, 51 patients (18%) without cytogenetic data were placed in the unknown group.
Transplantation procedure
The conditioning regimen consisted of either a total body irradiation (TBI)-based regimen (n ¼ 173) or a chemotherapybased regimen (n ¼ 110). In all, 218 patients received bone marrow grafts, while 65 received peripheral blood stem cell grafts. Prophylaxis against graft-versus-host disease (GVHD) mainly consisted of cyclosporine with or without methotrexate (n ¼ 273), whereas nine patients received tacrolimus-based prophylaxis. One patient received no prophylaxis. Acute and chronic GVHD were scored according to the classic Seattle criteria.
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Statistical considerations
The primary end point of this study was overall survival (OS) after allo-SCT. Disease-free survival (DFS) and cumulative incidences of relapse, nonrelapse mortality, and acute and chronic GVHD were evaluated as secondary end points. The probabilities of OS and DFS and the cumulative incidence of acute GVHD were calculated using the Kaplan-Meier method. Cumulative incidences of relapse and nonrelapse mortality were calculated using Gray's method, considering each other risk as a competing risk. 11 Univariate comparisons for dichotomous variables between groups were performed with Fisher's exact test or the w 2 -test and multivariate analyses were performed using logistic regression analysis. Proportional hazards modeling was used to assess the influence of confounding factors on timeto-event variables. Potential confounding factors considered in the analysis were recipient age, sex, FAB classification, karyotype, preparative regimen, stem cell source, and the history of chemotherapy before transplantation. The effect of the development of acute and chronic GVHD on the incidence of relapse was analyzed among patients who survived without relapse at 60 and 150 days after transplantation, respectively. This landmark analysis was used to exclude bias that may arise from including patients who died too early to develop GVHD in the group without GVHD.
Results
Patient characteristics
The patient characteristics are summarized in Table 1 . There were 171 males and 112 females. The median age at allo-SCT was 41 years (range 16-65 years). The median duration from diagnosis to allo-SCT was 8 months (range 1-204 months). A total of 188 patients had received chemotherapy before allo-SCT (Chemo group), whereas 95 had not (NoChemo group). Among the Chemo group, 81 underwent allo-SCT in complete remission (CR), while 107 were not in remission (NR). The Chemo group included a significantly higher proportion of patients with advanced disease than the NoChemo group (Po0.0001). In addition, the proportion of patients with a poor karyotype was significantly higher in the Chemo group (P ¼ 0.004).
Survival
Of the 283 patients, 159 were alive with a median follow-up of 36.5 months (range 1-139 months). The Kaplan-Meier probability of OS was 67.9% (95% confidence interval (CI) 63.4-72.4%) at 1 year, 48.8% (95% CI 44.7-52.9%) at 5 years, and 42.5% (95% CI 38. .3%) at 10 years ( Figure 1 ). The OS and DFS curves are superimposed, since only 13 patients were alive after relapse at this analysis. In a univariate analysis, age younger than 40 years, disease duration of 1 year or longer, good karyotype, diagnosis of RA, and the NoChemo group were associated with longer OS (Table 2) . Among these factors, FAB classification, karyotype, and the history of chemotherapy were identified as independent significant prognostic factors for OS (Table 2, Figure 2 ).
Value of chemotherapy before transplantation
To determine the value of chemotherapy before transplantation in further detail, we only analyzed 139 patients with RAEB-t or LT to exclude biases, since the Chemo group included a significantly higher proportion of patients with RAEB-t and LT. Twenty-eight patients belonged to the NoChemo group and 111 patients belonged to the Chemo group. The proportion of Allograft from HLA-identical sibling for MDS K Nakai et al patients with a poor karyotype was equivalent between the 2 groups (39 vs 45%, P ¼ 0.44). The duration from diagnosis to allo-SCT was shorter in the NoChemo group, with a marginal significance (161 vs 248 days in median, P ¼ 0.07). Among the Chemo group, 43 were in CR and 68 were in NR at allo-SCT. The survival curves of the NoChemo group and CR patients in the Chemo group were superimposed (57 vs 54%, P ¼ 0.81), whereas patients who underwent allo-SCT in NR after chemotherapy showed significantly shorter survival (20%, Figure 3a) . The cumulative incidence of relapse was 26.2% in the NoChemo group and 27.6% in CR patients in the Chemo group (P ¼ 0.83, Figure 3b ). Nonrelapse mortality was also similar between the two groups (18.8 vs 17.8%, P ¼ 0.86, Figure 3c ). In contrast, the cumulative incidence of nonrelapse mortality was significantly higher in NR patients in the Chemo group than the NoChemo group (48.9 vs 18.8%, P ¼ 0.014), whereas difference in the incidence of relapse was not statistically significant (35.0 vs 26.2%, P ¼ 0.44).
The role of chemotherapy was also examined in patients with less-advanced MDS (RA or RAEB). Survival in the NoChemo group, CR patients in the Chemo group, and NR patients in the Chemo group was 73.4, 58.2, and 50.0% at 5 years, respectively. This difference was not statistically significant (P ¼ 0.11). 
Figure 2
Overall survival grouped according to significant independent prognostic factors. Patients who lacked information regarding the history of chemotherapy before transplantation were included in (c).
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Influence of acute and chronic GVHD on relapse
The cumulative incidence of grade II-IV and III-IV acute GVHD among those who achieved engraftment was 33 and 10%, respectively. Independent significant risk factors for grade II-IV acute GVHD were the karyotype (relative risk (RR) 1.98, 3.02, and 1.87, P ¼ 0.016, 0.0005, and 0.047 for intermediate, poor, and unknown groups, respectively) and the absence of a previous history of chemotherapy (RR 1.64, P ¼ 0.033). Chronic GVHD developed in 110 (53%) of 209 patients who survived more than 100 days. Logistic regression analysis identified higher age and the use of peripheral blood stem cell graft as independent significant risk factors for the development of chronic GVHD (RR 1.75 and 2.97, P ¼ 0.049 and 0.019, respectively). The cumulative incidence of relapse in those who developed grade II-IV acute GVHD and those who did not was 39.6 and 19.5%, respectively (P ¼ 0.086). The cumulative incidence of relapse in those who developed chronic GVHD and those who did not was 22.0 and 20.8%, respectively (P ¼ 0.82).
Discussion
Although intensive chemotherapy may cure rare young patients with advanced MDS, 10, 12 allo-SCT is the only curative treatment for most MDS patients. The recent application of nonmyeloablative or reduced-intensity conditioning extended the indication of allo-SCT to older patients with MDS. 13, 14 Factors known to be associated with the outcome of allo-SCT include patient age, disease duration, bone marrow blast counts, FAB classification, karyotype, and IPSS. [1] [2] [3] [4] 7, 15, 16 The fact that a lower bone marrow blast count before allo-SCT was associated with a better outcome after allo-SCT has encouraged physicians to administer intensive chemotherapy before allo-SCT. In fact, two registry reports from the European Group for Blood and Marrow Transplantation (EBMT) and National Marrow Donation Program showed that DFS for patients who underwent allo-SCT in first complete remission was better than that for patients who underwent allo-SCT as primary treatment for RAEB-t or LT. 1, 2 However, this might only reflect the fact that patients with disease that originally responded well to chemotherapy were selected in the low blast count group. Also, these studies did not take into account patients who received induction chemotherapy but died or developed toxicity that precluded allo-SCT. Thus, these data do not justify the administration of induction chemotherapy before allo-SCT.
Runde et al 16 analyzed the outcome of patients who underwent BMT from HLA-identical siblings as first-line treatment for MDS and were reported to the EBMT. OS at 5 years was 42, 24, and 28% for patients with RAEB, RAEB-t, and LT, respectively. They concluded that allo-SCT should be performed as primary treatment for patients with a low blast cell count. Anderson et al 17 retrospectively compared the outcome of allo-SCT as an initial treatment for secondary AML and that of allo-SCT for chemotherapy-sensitive secondary AML. DFS at 5 years was not significantly different (24 vs 15%, P ¼ 0.33). The findings of the present analysis of JSHCT registry data were similar. OS at 5 years was 57% for patients who underwent allo-SCT for RAEB-t or LT without induction chemotherapy and 54% for those who underwent allo-SCT in remission (P ¼ 0.81). The difference was not significant even after adjusting for age and karyotype (RR 0.90, P ¼ 0.80). Although there might be a bias that patients with an indolent clinical outcome tended to undergo allo-SCT without induction chemotherapy, it was unlikely, because the duration from diagnosis to transplantation was rather shorter in the NoChemo group. Thus, the administration of remission induction chemotherapy before allo-SCT was not recommended from these data.
Information regarding the type of chemotherapy was not collected in this study and thus, it was supposed that low-dose Overall survival (a) and cumulative incidences of relapse (b) and nonrelapse mortality (c) grouped according to the presence or absence of previous history of chemotherapy. These are compared between patients who achieved remission after chemotherapy and those who did not undergo chemotherapy. Only patients with RAEB-t or LT were included in the analyses.
Allograft from HLA-identical sibling for MDS K Nakai et al chemotherapy was also included, especially in patients with RA. However, most CR patients in the Chemo group must have received AML-type intensive chemotherapy, because CR can be rarely achieved with low-dose chemotherapy. A major shortcoming of this analysis was the lack of information regarding blast cell count at the time of transplantation. However, in the comparison between NoChemo group and CR patients in the Chemo group, blast count at transplantation was greater than 20% in the former group, whereas it was less than 5% in the latter group, because only patients with RAEB-t or LT were included in this analysis. Nevertheless, survival after transplantation was similar between the two groups.
We did not collect data of patients who underwent induction chemotherapy but did not proceed to allo-SCT. It was supposed that there were many patients who gave up transplantation due to lack of response to chemotherapy or toxicity of chemotherapy. Therefore, the CR patients in the Chemo group included only patients who had good response to chemotherapy and maintained good physical condition enough to undergo allo-SCT. Nevertheless, survival after transplantation was similar between the NoChemo group and the CR patients in the Chemo group.
OS at 5 years among patients with RAEB-t or LT in this study was better than those in previous reports. Considering the relapse rate of 26-27% and nonrelapse mortality rate of 17-18%, this good outcome resulted from the low nonrelapse mortality rate, probably due to the low incidence of acute GVHD. Not only the homogeneity of HLA and minor histocompatibility antigens but also the high frequency of the IL10-592A allele among the Japanese population may account for the low incidence of severe acute GVHD. [18] [19] [20] The study from IBMTR did not demonstrate that the development of acute or chronic GVHD affected the incidence of relapse after allo-SCT from an HLA-identical sibling donor, 4 while the NMDP study showed that patients who developed grade II-IV acute GVHD had a lower incidence of relapse after allo-SCT from an unrelated donor than those who did not develop acute GVHD. 1 In this study, the development of GVHD did not appear to have a positive impact on the incidence of relapse. This discrepancy might be explained by a hypothesis that an anti-MDS effect associated with GVHD may be stronger in unrelated allo-SCT than in that from an HLA-identical sibling donor. Also, the anti-MDS effect associated with GVHD in this study might have been masked by the bias that the incidence of GVHD was significantly higher in patients with a poor karyotype.
In conclusion, this study confirmed that allo-SCT from an HLA-identical sibling donor offers the potential for long-term survival in patients with MDS. Induction chemotherapy before allo-SCT did not appear to offer any benefit. Although only a randomized controlled trial will be able to establish a definite conclusion, it seems that allo-SCT may be beneficial as primary treatment for patients with a low blast cell count or those with an advanced disease but with an indolent clinical course. Relapse is the major cause of failure after allo-SCT for advanced MDS, but we should not intend to induce GVHD, since GVHD did not appear to have a clear beneficial effect on the incidence of relapse.
